Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Foundation Medicine and Novartis have reached a 3 year agreement to use Foundation’s clinical grade, next-generation sequencing to support the drug firm’s clinical oncology programs. The agreement builds on a 2011 deal between the firms and calls for the use of Foundation Medicine’s molecular information platform across many of Novartis’ Phase 1 and Phase 2 oncology clinical programs. The initial collaboration generated “very interesting” data, and this type of tumor genomic profiling has become an important part of Novartis’ clinical trials, Foundation Medicine said.

Foundation Medicine added that it may develop additional diagnostic products from the partnership.

“The comprehensive molecular assessment of Novartis’ Oncology clinical trial samples is expected to help to bring potentially lifesaving therapies to the right patients more quickly, and we expect that the wealth of molecular information will help fundamentally improve the way cancer is understood and treated,” Michael Pellini, president and CEO of Foundation Medicine, said in a statement.

Source:

http://www.genomeweb.com/sequencing/foundation-medicine-novartis-ink-new-deal-clinical-oncology-programs

Reported by: Dr. V.S.Karra, Ph.D.